Role of presynaptic α2-adrenoceptors in antidepressant action: Recent findings from microdialysis studies

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 5, 2004, Pages 819-827

  Invernizzi, Roberto W ^a   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

2 adrenoceptor antagonists; 2 adrenoceptors; 1 (2 pyrimidinyl)piperazine; 1 PP; 5 HT; A; Antidepressant drugs; atipamezole; CC; cingulate cortex; DA; Microdialysis; Noradrenaline; Noradrenaline reuptake inhibitors; serotonin

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINEPTINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; COCAINE; DESIPRAMINE; DULOXETINE; IDAZOXAN; NISOXETINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SIBUTRAMINE; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; NORADRENALIN;

DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; LOW DRUG DOSE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENERGIC NERVE; NORADRENERGIC SYSTEM; PRESYNAPTIC NERVE; RECEPTOR BLOCKING; REVIEW; SYNAPSE; ANIMAL; BIOLOGICAL MODEL; DEPRESSION; EXTRACELLULAR SPACE; METABOLISM; METHODOLOGY; PHYSIOLOGY; SYNAPTOSOME;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; EXTRACELLULAR SPACE; HUMANS; MICRODIALYSIS; MODELS, NEUROLOGICAL; NOREPINEPHRINE; PRESYNAPTIC TERMINALS; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 4444355123     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.05.026     Document Type: Review

References (84)

1. Abercrombie E.D., Keller R.W. Jr., Zigmond M.J. Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies. Neuroscience. 27:1988;897
2. Barker E.I., Blakely R.D. Norepinephrine and serotonin transporters. Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;321 Raven Press, New York
3. Bel N., Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 15:1993;243
4. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl.). 94:1988;147
5. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 27:2002;699
6. Callado L.F., Meana J.J., Grijalba B., Pazos A., Sastre M., Garcia-Sevilla J.A. Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J. Neurochem. 70:1998;1114
7. Cedarbaum J.M., Aghajanian G.K. Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res. 112:1976;413
8. Cervo L., Grignaschi G., Samanin R. Alpha 2-adrenoceptor blockade prevents the effect of desipramine in the forced swimming test. Eur. J. Pharmacol. 175:1990;301
9. Charney D.S., Price L.H., Heninger G.R. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch. Gen. Psychiatry. 43:1986;1155
10. Cryan J.F., Page M.E., Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur. J. Pharmacol. 436:2002;197
11. Daniel W., Melzacka M. A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine. J. Pharm. Pharmacol. 44:1992;429
12. Dawson L.A., Nguyen H.Q., Geiger A. Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology. 38:1999;1153
13. Dazzi L., Serra M., Spiga F., Pisu M.G., Jentsch J.D., Biggio G. Prevention of the stress-induced increase in frontal cortical dopamine efflux of freely moving rats by long-term treatment with antidepressant drugs. Eur. Neuropsychopharmacol. 11:2001;343
14. Dazzi L., Seu E., Cherchi G., Biggio G. Antagonism of the stress-induced increase in cortical norepinephrine output by the selective norepinephrine reuptake inhibitor reboxetine. Eur. J. Pharmacol. 476:2003;55
15. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Heninger G.R., Gelenberg A.J., Charney D.S. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 29:1993;389
16. Delgado P.L., Moreno F.A., Onate L., Gelenberg A.J. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int. J. Neuropsychopharmacol. 5:2002;63
17. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 241:1987;642
18. Dostert P., Benedetti M.S., Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur. Neuropsychopharmacol. 7(Suppl. 1):1997;S23
19. Engleman E.A., Perry K.W., Mayle D.A., Wong D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 12:1995;287
20. Esposito E., Ossowska G., Samanin R. Further evidence that noradrenaline is not involved in the anti-immobility activity of chronic desipramine in the rat. Eur. J. Pharmacol. 136:1987;429
21. Florin S.M., Kuczenski R., Segal D.S. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res. 654:1994;53
22. Florin-Lechner S.M., Druhan J.P., Aston-Jones G., Valentino R.J. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 742:1996;89
23. Gobert A., Rivet J.M., Cistarelli L., Melon C., Millan M.J. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J. Neurochem. 69:1997;2616
24. Gonzalez A.M., Pascual J., Meana J.J., Barturen F., del Arco C., Pazos A., Garcia-Sevilla J.A. Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J. Neurochem. 63:1994;256
25. Heal D.J., Prow M.R., Buckett W.R. Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic alpha 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride. Psychopharmacology (Berl.). 103:1991;251
26. Hjorth S. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J. Neurochem. 60:1993;776
27. Invernizzi R., Belli S., Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584:1992;322
28. Invernizzi R., Pozzi L., Vallebuona F., Bonini I., Sacchetti G., Samanin R. Effect of amineptine on regional extracellular concentrations of dopamine and noradrenaline in the rat brain. J. Pharmacol. Exp. Ther. 262:1992;769
29. Invernizzi R., Bramante M., Samanin R. Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. Eur. J. Pharmacol. 260:1994;243
30. Invernizzi R., Bramante M., Samanin R. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 54:1996;143
31. Invernizzi R., Velasco C., Bramante M., Longo A., Samanin R. Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology. 36:1997;467
32. Invernizzi R.W., Parini S., Sacchetti G., Fracasso C., Caccia S., Annoni K., Samanin R. Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex. Br. J. Pharmacol. 132:2001;183
33. L'Heureux R., Dennis T., Curet O., Scatton B. Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J. Neurochem. 46:1986;1794
34. Lacroix D., Blier P., Curet O., de Montigny C. Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain. J. Pharmacol. Exp. Ther. 257:1991;1081
35. Lauritzen L., Clemmesen L., Klysner R., Loldrup D., Lunde M., Schaumburg E., Waarst S., Bech P. Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatry. 25:1992;182
36. Li M.Y., Yan Q.S., Coffey L.L., Reith M.E. Extracellular dopamine, norepinephrine, and serotonin in the nucleus accumbens of freely moving rats during intracerebral dialysis with cocaine and other monoamine uptake blockers. J. Neurochem. 66:1996;559
37. Linner L., Arborelius L., Nomikos G.G., Bertilsson L., Svensson T.H. Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade. Biol. Psychiatry. 46:1999;766
38. Lorang D., Amara S.G., Simerly R.B. Cell-type-specific expression of catecholamine transporters in the rat brain. J. Neurosci. 14:1994;4903
39. Maes M., Libbrecht I., van Hunsel F., Campens D., Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19:1999;177
40. Masson J., Sagne C., Hamon M., El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51:1999;439
41. Mateo Y., Pineda J., Meana J.J. Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem. 71:1998;790
42. Mateo Y., Fernandez-Pastor B., Meana J.J. Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br. J. Pharmacol. 133:2001;1362
43. Maura G., Bonanno G., Raiteri M. Presynaptic alpha 2-adrenoceptors mediating inhibition of noradrenaline and 5-hydroxytryptamine release in rat cerebral cortex: further characterization as different alpha 2-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;410
44. McMillen B.A., Warnack W., German D.C., Shore P.A. Effects of chronic desipramine treatment on rat brain noradrenergic responses to alpha-adrenergic drugs. Eur. J. Pharmacol. 61:1980;239
45. Meana J.J., Barturen F., Garcia-Sevilla J.A. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol. Psychiatry. 31:1992;471
46. Miller H.L., Delgado P.L., Salomon R.M., Heninger G.R., Charney D.S. Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology. 14:1996;151
47. Moore R.Y., Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2:1979;113
48. Moreno F.A., Gelenberg A.J., Bachar K., Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J. Clin. Psychiatry. 58:1997;437
49. Moret C., Briley M. Effect of milnacipran and desipramine on noradrenergic alpha 2-autoreceptor sensitivity. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 18:1994;1063
50. Ordway G.A., Widdowson P.S., Smith K.S., Halaris A. Agonist binding to alpha 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J. Neurochem. 63:1994;617
51. Osman O.T., Rudorfer M.V., Potter W.Z. Chronic alpha-2 antagonism increases norepinephrine, blocks GH release and is antidepressant. Biol. Psychiatry. 25:1989;197A
52. Page M.E., Lucki I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology. 27:2002;237
53. Palij P., Stamford J.A. Real-time monitoring of endogenous noradrenaline release in rat brain slices using fast cyclic voltammetry: 3. Selective detection of noradrenaline efflux in the locus coeruleus. Brain Res. 634:1994;275
54. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594
55. Perez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch. Gen. Psychiatry. 56:1999;375
56. Pineyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51:1999;533
57. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379
58. Raiteri M., Bonanno G., Maura G., Pende M., Andrioli G.C., Ruelle A. Subclassification of release-regulating alpha 2-autoreceptors in human brain cortex. Br. J. Pharmacol. 107:1992;1146
59. Reneric J.P., Bouvard M., Stinus L. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Neuropsychopharmacology. 24:2001;379
60. Riva M., Brunello N., Rovescalli A.C., Galimberti R., Carfagna N., Carminati P., Pozzi O., Ricciardi S., Roncucci R., Rossi A., Racagni G. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J. Drug. Dev. 1:1989;243
61. Robinson T.E., Justice J.B. Microdialysis in the Neurosciences. Houston J.P. Techniques in the Behavioral and Neural Sciences, vol. 7. 1991;1-450 Elsevier, Düsseldorf
62. Sacchetti G., Bernini M., Bianchetti A., Parini S., Invernizzi R.W., Samanin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br. J. Pharmacol. 128:1999;1332
63. Sacchetti G., Bernini M., Gobbi M., Parini S., Pirona L., Mennini T., Samanin R. Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 363:2001;66
64. Schmauss M., Laakmann G., Dieterle D. Effects of alpha 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression. J. Clin. Psychopharmacol. 8:1988;108
65. Scott J.A., Crews F.T. Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant alpha-2 antagonist treatment. J. Pharmacol. Exp. Ther. 224:1983;640
66. Seo D.O., Shin C.Y., Lee C.J., Dailey J.W., Reith M.E., Jobe P.C., Ko K.H. Effect of alterations in extracellular norepinephrine on adrenoceptors: a microdialysis study in freely moving rats. Eur. J. Pharmacol. 365:1999;39
67. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev. Physiol., Biochem. Pharmacol. 77:1977;1
68. Svensson T.H., Usdin T. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha-receptor mediation. Science. 202:1978;1089
69. Szabo S.T., Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur. J. Neurosci. 13:2001;2077
70. Tanda G., Frau R., Di Chiara G. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology (Berl.). 127:1996;83
71. Tejani-Butt S.M. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther. 260:1992;427
72. Thomas D.N., Holman R.B. A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J. Neurochem. 56:1991;1741
73. Thomas D.N., Post R.M., Pert A. Focal and systemic cocaine differentially affect extracellular norepinephrine in the locus coeruleus, frontal cortex and hippocampus of the anaesthetized rat. Brain Res. 645:1994;135
74. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12:1997;81
75. Ungerstedt U. Measurement of neurotransmitter release by intracranial dialysis. Marsden C.A. Measurement of Neurotransmitter Release in Vivo. 1984;81 Wiley, New York
76. Van Gaalen M., Kawahara H., Kawahara Y., Westerink B.H. The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. Brain Res. 763:1997;56
77. van Veldhuizen M.J., Feenstra M.G., Boer G.J. Regional differences in the in vivo regulation of the extracellular levels of noradrenaline and its metabolites in rat brain. Brain Res. 635:1994;238
78. Westfall T.C. Local regulation of adrenergic neurotransmission. Physiol. Rev. 57:1977;659
79. Wiech N.L., Ursillo R.C. Acceleration of desipramine-induced decrease of rat corticocerebral beta-adrenergic receptors by yohimbine. Commun. Psychopharmacol. 4:1980;95
80. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry. 47:2000;818
81. Wortley K.E., Heal D.J., Stanford S.C. Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors. Br. J. Pharmacol. 128:1999;659
82. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J. Clin. Psychopharmacol. 17:1997;446
83. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J. Clin. Psychopharmacol. 18:1998;441
84. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., Dotoli D., Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry. 50:2001;323